Trade Amarin Corporation plc - AMRN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.0335 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Amarin Corporation PLC ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 0.7656 |
Open* | 0.7573 |
1-Year Change* | -32.57% |
Day's Range* | 0.7373 - 0.7696 |
52 wk Range | 0.65-2.23 |
Average Volume (10 days) | 1.12M |
Average Volume (3 months) | 34.52M |
Market Cap | 313.72M |
P/E Ratio | -100.00K |
Shares Outstanding | 408.29M |
Revenue | 322.44M |
EPS | -0.13 |
Dividend (Yield %) | N/A |
Beta | 2.11 |
Next Earnings Date | Feb 14, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Nov 30, 2023 | 0.7656 | 0.0310 | 4.22% | 0.7346 | 0.7773 | 0.7232 |
Nov 29, 2023 | 0.7378 | 0.0124 | 1.71% | 0.7254 | 0.7573 | 0.7183 |
Nov 28, 2023 | 0.7365 | -0.0110 | -1.47% | 0.7475 | 0.7577 | 0.7193 |
Nov 27, 2023 | 0.7658 | 0.0106 | 1.40% | 0.7552 | 0.7773 | 0.7380 |
Nov 24, 2023 | 0.7793 | 0.0081 | 1.05% | 0.7712 | 0.7799 | 0.7565 |
Nov 22, 2023 | 0.7592 | 0.0038 | 0.50% | 0.7554 | 0.7743 | 0.7315 |
Nov 21, 2023 | 0.7524 | -0.0218 | -2.82% | 0.7742 | 0.7941 | 0.7512 |
Nov 20, 2023 | 0.7791 | -0.0135 | -1.70% | 0.7926 | 0.8155 | 0.7740 |
Nov 17, 2023 | 0.8041 | 0.0647 | 8.75% | 0.7394 | 0.8179 | 0.7263 |
Nov 16, 2023 | 0.7548 | 0.0102 | 1.37% | 0.7446 | 0.7644 | 0.7149 |
Nov 15, 2023 | 0.7473 | 0.0139 | 1.90% | 0.7334 | 0.7778 | 0.7334 |
Nov 14, 2023 | 0.7479 | 0.0534 | 7.69% | 0.6945 | 0.7536 | 0.6880 |
Nov 13, 2023 | 0.6881 | -0.0137 | -1.95% | 0.7018 | 0.7047 | 0.6773 |
Nov 10, 2023 | 0.7114 | -0.0259 | -3.51% | 0.7373 | 0.7473 | 0.6831 |
Nov 9, 2023 | 0.7273 | -0.0191 | -2.56% | 0.7464 | 0.7593 | 0.7152 |
Nov 8, 2023 | 0.7413 | -0.0309 | -4.00% | 0.7722 | 0.7722 | 0.7337 |
Nov 7, 2023 | 0.7718 | 0.0075 | 0.98% | 0.7643 | 0.7732 | 0.7412 |
Nov 6, 2023 | 0.7667 | 0.0553 | 7.77% | 0.7114 | 0.8003 | 0.7114 |
Nov 3, 2023 | 0.7189 | 0.0523 | 7.85% | 0.6666 | 0.7248 | 0.6531 |
Nov 2, 2023 | 0.6548 | -0.0202 | -2.99% | 0.6750 | 0.7068 | 0.6483 |
Amarin Corporation plc Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, February 14, 2024 | ||
Time (UTC) 07:00 | Country IE
| Event Q4 2023 Amarin Corporation PLC Earnings Release Q4 2023 Amarin Corporation PLC Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 369.193 | 583.187 | 614.06 | 429.755 | 229.214 |
Revenue | 369.193 | 583.187 | 614.06 | 429.755 | 229.214 |
Cost of Revenue, Total | 108.631 | 121.327 | 131.444 | 96.019 | 54.543 |
Gross Profit | 260.562 | 461.86 | 482.616 | 333.736 | 174.671 |
Total Operating Expense | 475.062 | 572.685 | 633.715 | 454.034 | 337.439 |
Selling/General/Admin. Expenses, Total | 304.416 | 408.334 | 463.312 | 323.623 | 226.996 |
Research & Development | 30.411 | 29.307 | 38.959 | 34.392 | 55.2 |
Unusual Expense (Income) | 31.604 | 13.717 | |||
Operating Income | -105.869 | 10.502 | -19.655 | -24.279 | -108.225 |
Interest Income (Expense), Net Non-Operating | 2.804 | 1.091 | 2.296 | 1.873 | -7.798 |
Other, Net | -0.74 | -0.302 | 0.104 | -0.075 | -0.326 |
Net Income Before Taxes | -103.805 | 11.291 | -17.255 | -22.481 | -116.349 |
Net Income After Taxes | -105.803 | 7.729 | -18 | -22.645 | -116.445 |
Net Income Before Extra. Items | -105.803 | 7.729 | -18 | -22.645 | -116.445 |
Net Income | -105.803 | 7.729 | -18 | -22.645 | -116.445 |
Total Adjustments to Net Income | |||||
Income Available to Common Excl. Extra. Items | -105.803 | 7.729 | -18 | -22.645 | -116.445 |
Income Available to Common Incl. Extra. Items | -105.803 | 7.729 | -18 | -22.645 | -116.445 |
Diluted Net Income | -105.803 | 7.729 | -18 | -22.645 | -116.445 |
Diluted Weighted Average Shares | 401.155 | 402.48 | 381.759 | 342.538 | 297.237 |
Diluted EPS Excluding Extraordinary Items | -0.26375 | 0.0192 | -0.04715 | -0.06611 | -0.39176 |
Diluted Normalized EPS | -0.21254 | 0.04253 | -0.04715 | -0.06611 | -0.39176 |
Total Extraordinary Items | 0 | 0 | |||
Depreciation / Amortization | 0.7 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 80.167 | 85.975 | 90.245 | 89.878 | 94.44 |
Revenue | 80.167 | 85.975 | 90.245 | 89.878 | 94.44 |
Cost of Revenue, Total | 23.199 | 25.794 | 26.641 | 23.941 | 35.81 |
Gross Profit | 56.968 | 60.181 | 63.604 | 65.937 | 58.63 |
Total Operating Expense | 104.126 | 103.316 | 99.831 | 95.022 | 157.272 |
Selling/General/Admin. Expenses, Total | 50.953 | 59.587 | 68.131 | 58.745 | 86.893 |
Research & Development | 5.642 | 5.681 | 5.239 | 5.765 | 9.356 |
Operating Income | -23.959 | -17.341 | -9.586 | -5.144 | -62.832 |
Interest Income (Expense), Net Non-Operating | 3.001 | 2.221 | 1.563 | 0.75 | 0.288 |
Other, Net | 3.043 | 0.624 | 1.25 | 0.511 | -2.255 |
Net Income Before Taxes | -17.915 | -14.496 | -6.773 | -3.883 | -64.799 |
Net Income After Taxes | -17.56 | -16.46 | 0.856 | -5.14 | -69.956 |
Net Income Before Extra. Items | -17.56 | -16.46 | 0.856 | -5.14 | -69.956 |
Net Income | -17.56 | -16.46 | 0.856 | -5.14 | -69.956 |
Income Available to Common Excl. Extra. Items | -17.56 | -16.46 | 0.856 | -5.14 | -69.956 |
Income Available to Common Incl. Extra. Items | -17.56 | -16.46 | 0.856 | -5.14 | -69.956 |
Diluted Net Income | -17.56 | -16.46 | 0.856 | -5.14 | -69.956 |
Diluted Weighted Average Shares | 407.848 | 406.177 | 404.788 | 404.614 | 398.187 |
Diluted EPS Excluding Extraordinary Items | -0.04306 | -0.04052 | 0.00211 | -0.0127 | -0.17569 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.00428 | -0.02091 | 0.00183 | -0.00215 | -0.13453 |
Unusual Expense (Income) | 24.332 | 12.254 | -0.18 | 6.571 | 25.213 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 689.098 | 878.727 | 879.233 | 855.005 | 377.997 |
Cash and Short Term Investments | 309.361 | 454.128 | 500.933 | 644.588 | 249.227 |
Cash & Equivalents | 217.666 | 219.454 | 186.964 | 644.588 | 249.227 |
Total Receivables, Net | 130.99 | 163.653 | 154.574 | 116.43 | 66.523 |
Accounts Receivable - Trade, Net | 130.99 | 163.653 | 154.574 | 116.43 | 66.523 |
Total Inventory | 228.732 | 234.676 | 188.864 | 76.769 | 57.802 |
Prepaid Expenses | 19.492 | 22.352 | 30.947 | 13.311 | 2.945 |
Other Current Assets, Total | 0.523 | 3.918 | 3.915 | 3.907 | 1.5 |
Total Assets | 886.179 | 1068.06 | 966.021 | 882.209 | 385.714 |
Property/Plant/Equipment, Total - Net | 9.948 | 9.085 | 10.07 | 10.872 | 0.063 |
Property/Plant/Equipment, Total - Gross | 12.42 | 11.006 | 11.686 | 11.891 | 0.902 |
Accumulated Depreciation, Total | -2.472 | -1.921 | -1.616 | -1.019 | -0.839 |
Intangibles, Net | 21.78 | 23.547 | 13.817 | 15.258 | 7.48 |
Other Long Term Assets, Total | 164.078 | 121.71 | 0.432 | 1.074 | 0.174 |
Total Current Liabilities | 259.479 | 370.682 | 307.443 | 242.248 | 157.263 |
Accounts Payable | 64.602 | 114.922 | 105.876 | 49.95 | 37.632 |
Accrued Expenses | 157.035 | 207.509 | 169.855 | 123.24 | 76.459 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 50.13 | 34.24 | ||
Other Current Liabilities, Total | 37.842 | 48.251 | 31.712 | 18.928 | 8.932 |
Total Liabilities | 290.846 | 400.966 | 338.516 | 273.946 | 233.384 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 46.108 |
Long Term Debt | 0 | 46.108 | |||
Other Liabilities, Total | 31.367 | 30.284 | 31.073 | 31.698 | 30.013 |
Total Equity | 595.333 | 667.099 | 627.505 | 608.263 | 152.33 |
Redeemable Preferred Stock | 0 | 21.85 | 21.85 | ||
Common Stock | 299.002 | 294.027 | 290.115 | 269.173 | 246.663 |
Additional Paid-In Capital | 1885.35 | 1855.25 | 1817.65 | 1764.32 | 1282.76 |
Retained Earnings (Accumulated Deficit) | -1527.25 | -1421.45 | -1429.18 | -1411.18 | -1388.53 |
Treasury Stock - Common | -61.77 | -60.726 | -51.082 | -35.9 | -10.413 |
Total Liabilities & Shareholders’ Equity | 886.179 | 1068.06 | 966.021 | 882.209 | 385.714 |
Total Common Shares Outstanding | 404.346 | 396.598 | 392.538 | 360.104 | 325.85 |
Total Preferred Shares Outstanding | 0 | 289.317 | 289.317 | ||
Short Term Investments | 91.695 | 234.674 | 313.969 | ||
Long Term Investments | 1.275 | 34.996 | 62.469 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 717.511 | 706.495 | 683.821 | 689.098 | 686.52 |
Cash and Short Term Investments | 320.662 | 312.914 | 304.371 | 309.361 | 303.701 |
Cash & Equivalents | 270.814 | 232.995 | 191.412 | 217.666 | 240.498 |
Short Term Investments | 49.848 | 79.919 | 112.959 | 91.695 | 63.203 |
Total Receivables, Net | 122.4 | 122.73 | 133.236 | 130.99 | 123.379 |
Accounts Receivable - Trade, Net | 122.4 | 122.73 | 133.236 | 130.99 | 123.379 |
Total Inventory | 254.461 | 227.021 | 225.813 | 228.732 | 227.606 |
Prepaid Expenses | 19.464 | 43.306 | 19.878 | 19.492 | 27.914 |
Other Current Assets, Total | 0.524 | 0.524 | 0.523 | 0.523 | 3.92 |
Total Assets | 839.031 | 860.018 | 860.188 | 886.179 | 908.303 |
Property/Plant/Equipment, Total - Net | 8.657 | 9.157 | 9.377 | 9.948 | 9.461 |
Intangibles, Net | 19.676 | 20.377 | 21.078 | 21.78 | 21.638 |
Long Term Investments | 0 | 0.067 | 0.544 | 1.275 | 2.264 |
Other Long Term Assets, Total | 93.187 | 123.922 | 145.368 | 164.078 | 188.42 |
Total Current Liabilities | 266.691 | 270.932 | 244.242 | 259.479 | 287.356 |
Accounts Payable | 53.362 | 54.309 | 58.779 | 64.602 | 93.157 |
Accrued Expenses | 211.304 | 214.598 | 183.264 | 192.678 | 192.001 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 2.025 | 2.025 | 2.199 | 2.199 | 2.198 |
Total Liabilities | 285.883 | 290.89 | 275.395 | 290.846 | 320.476 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 19.192 | 19.958 | 31.153 | 31.367 | 33.12 |
Total Equity | 553.148 | 569.128 | 584.793 | 595.333 | 587.827 |
Common Stock | 302.318 | 301.906 | 301.285 | 299.002 | 298.596 |
Additional Paid-In Capital | 1895.16 | 1891.96 | 1890.5 | 1885.35 | 1878.92 |
Retained Earnings (Accumulated Deficit) | -1580.58 | -1561.27 | -1543.71 | -1527.25 | -1528.11 |
Treasury Stock - Common | -63.743 | -63.464 | -63.277 | -61.77 | -61.585 |
Total Liabilities & Shareholders’ Equity | 839.031 | 860.018 | 860.188 | 886.179 | 908.303 |
Total Common Shares Outstanding | 408.551 | 408.134 | 407.266 | 404.346 | 403.829 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -105.803 | 7.729 | -18 | -22.645 | -116.445 |
Cash From Operating Activities | -180.092 | -66.537 | -21.746 | -9.366 | -94.703 |
Cash From Operating Activities | 0.551 | 0.587 | 0.597 | 0.18 | 0.023 |
Amortization | 2.545 | 2.27 | 1.441 | 0.679 | 0.646 |
Deferred Taxes | 0 | ||||
Non-Cash Items | 26.686 | 38.867 | 48.05 | 32.561 | 20.989 |
Cash Taxes Paid | -1.782 | 3.656 | 0.207 | 0.067 | 0.85 |
Cash Interest Paid | 0 | 2.043 | 4.591 | 21.527 | |
Changes in Working Capital | -104.071 | -115.99 | -53.834 | -20.141 | 0.084 |
Cash From Investing Activities | 175.288 | 104.103 | -376.963 | -2.478 | -0.058 |
Capital Expenditures | -0.599 | -0.252 | -2.478 | -0.058 | |
Cash From Financing Activities | -0.379 | -5.073 | -58.907 | 409.612 | 271.251 |
Financing Cash Flow Items | -1.044 | -9.644 | -15.686 | -25.487 | -6.344 |
Issuance (Retirement) of Stock, Net | 0.665 | 4.571 | 7.115 | 466.751 | 292.285 |
Issuance (Retirement) of Debt, Net | -50.336 | -31.652 | -14.69 | ||
Net Change in Cash | -5.183 | 32.493 | -457.616 | 397.768 | 176.49 |
Other Investing Cash Flow Items, Total | 175.887 | 104.103 | -376.711 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -16.46 | -105.803 | -106.659 | -101.519 | -31.563 |
Cash From Operating Activities | -7.008 | -180.092 | -181.644 | -163.431 | -98.847 |
Cash From Operating Activities | 0.063 | 0.551 | 0.426 | 0.288 | 0.144 |
Amortization | 0.702 | 2.545 | 1.909 | 1.273 | 0.636 |
Non-Cash Items | 4.649 | 26.686 | 20.358 | 15.299 | 6.452 |
Cash Taxes Paid | 0.038 | -1.782 | -1.49 | -2.112 | 0.051 |
Cash Interest Paid | |||||
Changes in Working Capital | 4.038 | -104.071 | -97.678 | -78.772 | -74.516 |
Cash From Investing Activities | -19.61 | 175.288 | 203.107 | 172.239 | 99.049 |
Capital Expenditures | -0.599 | ||||
Other Investing Cash Flow Items, Total | -19.61 | 175.887 | 203.107 | 172.239 | 99.049 |
Cash From Financing Activities | 0.364 | -0.379 | -0.417 | -0.261 | -0.505 |
Financing Cash Flow Items | -1.507 | -1.044 | -0.859 | -0.693 | -0.535 |
Issuance (Retirement) of Stock, Net | 1.871 | 0.665 | 0.442 | 0.432 | 0.03 |
Issuance (Retirement) of Debt, Net | |||||
Net Change in Cash | -26.254 | -5.183 | 21.046 | 8.547 | -0.303 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Sarissa Capital Management, L.P. | Hedge Fund | 7.183 | 29300000 | 24390000 | 2023-09-01 | LOW |
Kynam Capital Management LP | Hedge Fund | 2.9418 | 12000000 | 0 | 2023-06-30 | MED |
Morgan Stanley & Co. LLC | Research Firm | 2.669 | 10887204 | -312367 | 2023-06-30 | MED |
Eversept Partners, LP | Hedge Fund | 2.5746 | 10502109 | -4110648 | 2023-06-30 | HIGH |
Two Sigma Investments, LP | Hedge Fund | 1.9952 | 8138690 | -364758 | 2023-06-30 | HIGH |
Tang Capital Management, LLC | Hedge Fund | 1.7406 | 7100000 | 1700000 | 2023-06-30 | MED |
SCP Investment, LP | Hedge Fund | 1.5935 | 6500000 | 0 | 2023-06-30 | MED |
DG Capital Management, LLC | Investment Advisor/Hedge Fund | 1.3421 | 5474753 | 0 | 2023-06-30 | HIGH |
13D Management LLC | Investment Advisor | 1.0006 | 4081400 | -85500 | 2023-06-30 | MED |
ExodusPoint Capital Management, LP | Hedge Fund | 0.9545 | 3893310 | 3893310 | 2023-06-30 | HIGH |
Millennium Management LLC | Hedge Fund | 0.6035 | 2461684 | -3362066 | 2023-06-30 | HIGH |
Woodline Partners LP | Hedge Fund | 0.5516 | 2250000 | 250000 | 2023-06-30 | HIGH |
MFP Investors, LLC | Investment Advisor | 0.5442 | 2220000 | 106170 | 2023-06-30 | MED |
Longitude (Cayman) Ltd | Investment Advisor | 0.3395 | 1385000 | 135000 | 2023-06-30 | MED |
Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 0.325 | 1325894 | 18162 | 2023-06-30 | LOW |
Axxcess Wealth Management, LLC | Investment Advisor | 0.2989 | 1219328 | 500796 | 2023-06-30 | MED |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.2898 | 1182090 | -2125468 | 2023-06-30 | MED |
PSM Vermögensverwaltung GmbH | Investment Advisor | 0.2721 | 1110100 | 160000 | 2023-09-30 | HIGH |
Citadel Advisors LLC | Hedge Fund | 0.1891 | 771268 | -4349377 | 2023-06-30 | LOW |
OneDigital Investment Advisors LLC | Investment Advisor | 0.1856 | 757280 | -11500 | 2023-06-30 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Amarin Corporation plc Company profile
Amarin Corporation (AMRN) is a clinical-stage biopharmaceutical company focused on the commercialisation and improvement of therapeutics to cure and deal with cardiovascular diseases.
Established in 1989, Amarin is headquartered in Dublin, Ireland, and operates in several European countries, the United States, Canada, Lebanon and the United Arab Emirates.
The company’s lead commercial product VASCEPA (icosapent ethyl) is a prescription-only omega-3 fatty acid product. Taken as an adjunct to diet, it reduces triglyceride levels in adult patients suffering from severe hypertriglyceridemia. The drug helps to address cardiovascular risk for millions of patients.
VASCEPA was launched in the United States in 2013, but gained wider recognition in 2019 as the US Food and Drug Administration (FDA) approved Amarin for a broader indication for cardiovascular risk reduction in studied high-risk patients. It has also got approval from the European Commission to reduce the risks for cardiac patients.
Amarin still prices VASCEPA at a considerably lower level than other new drugs of its category.
Formerly known as Ethical Holdings, the company changed its name to Amarin Corporation in 1999. The company went public in July 2019. It trades on the Nasdaq under the ticker ‘AMRN’.
Industry: | Bio Therapeutic Drugs |
First Floor, Block 3, The Oval,
Shelbourne Road, Ballsbridge
DUBLIN
IE
Income Statement
- Annual
- Quarterly
News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com